JEFFREY MORRIS to Antibodies, Monoclonal
This is a "connection" page, showing publications JEFFREY MORRIS has written about Antibodies, Monoclonal.
Connection Strength
0.046
-
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. 2009 Feb 20; 27(6):843-50.
Score: 0.034
-
Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist. 2013; 18(12):1270-7.
Score: 0.012